The promising role of engineered T lymphocytes in immunotherapy for high-grade serous ovarian carcinoma: a review of mechanisms, clinical landscape, and future strategies
{{output}}
High-grade serous ovarian carcinoma (HGSC) demonstrates poor prognosis with approximately 80% recurrence rates and significant chemotherapy resistance. Conventional checkpoint inhibitors show limited efficacy (10-15%), necessitating alternative immunotherapeut... ...
